ActiveOps FY26 slides: ARR surges 46% as NRR hits 119%

ActiveOps reported FY26 total revenue of £45.0m (from £30.5m) and ARR of £41.5m, up 46% YoY, with organic ARR growth of 25% excluding the £5.9m Enlighten contribution. Adjusted EBITDA rose 72% to £4.3m, expanding margin to 10% (from 8%), while cash increased 16% to £23.8m and cash conversion hit 295%. SaaS net revenue retention jumped to 119% (from 106%) and Enlighten integration delivered £3.0m of annualized cost synergies; management reiterated an FY27 outlook with continued ARR growth expected in line with forecasts. The stock moved only +0.65% to $234, suggesting results were largely anticipated despite strong metrics.

Analysis

The important signal is not the revenue print; it is the quality of expansion. A 119% net retention rate and 295% cash conversion imply the product is already embedded enough to self-fund growth, which usually deserves a premium multiple. But the market’s muted response says investors want proof that this is scaling beyond the installed base: the salesforce expansion and partner build-out only matter if they convert into materially better new-logo productivity over the next 1-2 quarters.

Second-order, the company is trying to reframe itself from a niche workflow tool into an AI-enabled operating layer. That raises the bar for adjacent enterprise software names: buyers will increasingly compare any “AI” pitch against measurable labor savings and backlog reduction, not just model quality. If that discipline holds, vendors with softer ROI stories could see longer sales cycles, while consulting partners and Microsoft gain leverage as distribution multipliers if channel-led selling lowers acquisition cost.

The contrarian risk is that the story is already good enough for current expectations. The TAM expansion narrative and cross-sell pool are useful, but they do not change near-term capacity constraints: the real bottleneck is whether the enlarged commercial team can accelerate new account wins fast enough to offset inevitable saturation in the easiest expansion cohorts. The key falsifier over 1-3 months is any dip in organic ARR growth below the low-20s or a reversion in retention toward the historical range; that would suggest the current re-rating case is overstated.

Key Decisions for Investors

• AOM: Buy only on confirmation, not immediately. Wait for the next quarterly update to show sustained organic ARR growth above 20% and NRR above 115%; if that holds, the setup can support a 15-20% rerate over 3-6 months, but upside is limited if the market already priced the FY26 execution.
• AOM: If initiating now, keep size small and use a 2-quarter time stop. The thesis depends on salesforce productivity inflecting; if new-logo additions do not broaden materially by the next two reporting cycles, trim or exit as the multiple likely compresses back toward a slower-growth software peer set.
• SMNEY / TGT: No direct trade. The article has no economic linkage to these tickers, so treat them as noise and avoid forcing a correlation trade.
• Watch list: Long quality software baskets on pullbacks only if this print is confirmed by peers. Use IGV or WCLD as the liquid proxy for a broader SaaS-resilience view, but only if upcoming peer results also show retention/expansion staying firm; otherwise the read-through is company-specific, not sector-wide.